Committed to developing novel medicines to transform the lives of patients with life-altering central nervous system (CNS) disorders


Sage Therapeutics (NASDAQ: SAGE) is a clinical-stage biopharmaceutical company committed to developing novel medicines to transform the lives of patients with life-altering central nervous system (CNS) disorders. Sage has a portfolio of novel product candidates targeting critical CNS receptor systems, GABA and NMDA. Sage's lead program, a proprietary IV formulation of brexanolone (SAGE-547), has completed two Phase 3 clinical trials in postpartum depression.


Year Invested: 2011
Location: Cambridge, Mass.
Visit: www.sagerx.com

Recent News

December 5, 2018
Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

November 21, 2018
Sage Therapeutics to Present at Piper Jaffray 30th Annual Healthcare Conference

November 20, 2018
Sage Therapeutics Receives Notification of PDUFA Extension for ZULRESSOâ„¢ (brexanolone) Injection

Read More News

Associated Team Members

Kevin Starr
Partner